A Phase II Study of SYHA1813 for Recurrent or Progressive High-Grade Meningioma

Summary

This is a randomized, controlled, open-label, multicenter, Phase II clinical study designed to evaluate the efficacy and safety of SYHA1813 compared to investigators' choice in participants with recurrent or progressive high-grade meningioma.

Timeline

Start

2025-01-31

Primary completion

2027-01-31

Completion

2028-01-13

Drugs

Indications